A study led by researchers from University College London has found that individuals who suffered head injuries when they were aged 50-something or below attained below-average scores on cognitive tests administered when they were age 70.
The study’s findings, which were reported in the “Annals of Clinical and Translational Neurology,” found that while head injuries were not found to contribute to Alzheimer’s disease brain damage characteristics, they did make individuals more susceptible to symptoms of dementia.
Dr. Sarah-Naomi James, the lead author of the study, explained that the researchers found irrefutable proof that head injuries in mid or early life had a small but considerable effect on an individual’s thinking skills and brain health in the long term. This, she said, could be what sped up the normal aging process of the brain.
The study comprised of 502 participants; all participants were from the longest-running cohort study in the United Kingdom. The participants have been followed since they were born decades ago, the same week in 1946.
When they were aged 53, the participants were asked whether they had ever been knocked out in order to evaluate if they had ever experienced a significant head injury. From the sample, 21% admitted to being knocked out. Years late, when they were aged between 69 and 71, the participants took a series of cognitive tests and had MRI/PET brain scans taken.
When they were aged eight, all the participants had finalized standardized cognitive tests. Researchers compared their test results at age 70 and based their expected results off of their childhood cognition as well as other factors such as socioeconomic status and educational attainment.
They discovered that the participants aged 70 who had suffered a substantial head injury over a decade earlier performed marginally worse than was expected on cognitive tests that evaluated quick thinking and attention. Additionally, the researchers found that the participants had differences in the microstructural integrity of their brains and a 1% smaller brain volume. This discovery aligns with data from prior studies, which could explain the cognitive differences.
However, the researchers didn’t have access to data on the cause, severity or influence of these head injuries, which would have allowed them to see whether long-term effects may have been higher for some individuals.
UCL Dementia Research Center’s Professor Jonathan Schott, a joint senior author of the study, stated that the team’s findings added to evidence linking head injuries to brain health years later, adding that this was an additional reason to protect one’s brain from injury at all times.
Among the conditions afflicting the brains of older persons is Parkinson’s disease. For this and other diseases, XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is developing a number of drug candidates. For instance, XPhyto has a transdermal patch that is awaiting European market approval for the treatment of Parkinson’s.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
